pyridoxine has been researched along with Parkinson Disease in 80 studies
4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol: structure in first source
vitamin B6 : Any member of the group of pyridines that exhibit biological activity against vitamin B6 deficiency. Vitamin B6 deficiency is associated with microcytic anemia, electroencephalographic abnormalities, dermatitis with cheilosis (scaling on the lips and cracks at the corners of the mouth) and glossitis (swollen tongue), depression and confusion, and weakened immune function. Vitamin B6 consists of the vitamers pyridoxine, pyridoxal, and pyridoxamine and their respective 5'-phosphate esters (and includes their corresponding ionized and salt forms).
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To reduce the side effects in the medication of Parkinson and Asthma, pyridoxine (PY) is administered along with l-3,4-dihydroxyphenyl alanine (l-dopa) and theophylline (TP), respectively." | 7.83 | Highly sensitive interference-free electrochemical determination of pyridoxine at graphene modified electrode: Importance in Parkinson and Asthma treatments. ( Gowthaman, NS; John, SA; Raj, MA, 2016) |
| "VB6 deficiency anemia is typically microcytic, hypochromic, and sideroblastic." | 5.72 | Vitamin B6 Deficiency Anemia Attributed to Levodopa/Carbidopa Intestinal Gel Therapy for Parkinson's Disease: A Diagnostic Pitfall for Myelodysplastic Syndrome with Ring Sideroblasts. ( Ando, M; Hatano, T; Hattori, N; Honda, T; Komatsu, N; Tsutsui, M; Yasuda, H, 2022) |
| "To reduce the side effects in the medication of Parkinson and Asthma, pyridoxine (PY) is administered along with l-3,4-dihydroxyphenyl alanine (l-dopa) and theophylline (TP), respectively." | 3.83 | Highly sensitive interference-free electrochemical determination of pyridoxine at graphene modified electrode: Importance in Parkinson and Asthma treatments. ( Gowthaman, NS; John, SA; Raj, MA, 2016) |
| " This review summarises that available pharmacokinetic data involving levodopa, especially as it relates to therapeutic response of parkinsonian patients." | 2.35 | Clinical pharmacokinetics of levodopa in parkinson's disease. ( Bianchine, JR; Shaw, GM, 1976) |
| "VB6 deficiency anemia is typically microcytic, hypochromic, and sideroblastic." | 1.72 | Vitamin B6 Deficiency Anemia Attributed to Levodopa/Carbidopa Intestinal Gel Therapy for Parkinson's Disease: A Diagnostic Pitfall for Myelodysplastic Syndrome with Ring Sideroblasts. ( Ando, M; Hatano, T; Hattori, N; Honda, T; Komatsu, N; Tsutsui, M; Yasuda, H, 2022) |
| "Pyridoxine metabolism was investigated in eight chronic levodopa-treated parkinsonian patients and in eight matched dopa-naive controls by measurement of plasma and erythrocyte pyridoxal-5-phosphate concentrations over a 24-hour period, following intravenous administration of pyridoxine." | 1.25 | Effect of chronic levodopa treatment on pyridoxine metabolism. ( Mars, H, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 74 (92.50) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (1.25) | 29.6817 |
| 2010's | 1 (1.25) | 24.3611 |
| 2020's | 4 (5.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yasuda, H | 1 |
| Hatano, T | 1 |
| Honda, T | 1 |
| Tsutsui, M | 1 |
| Hattori, N | 1 |
| Ando, M | 1 |
| Komatsu, N | 1 |
| Lizárraga, KJ | 1 |
| Lang, AE | 1 |
| Sardoeira, A | 1 |
| Vila-Chã, N | 1 |
| Corrá, M | 1 |
| Sousa, AP | 1 |
| Maetzler, W | 1 |
| Maia, LF | 1 |
| Li, W | 1 |
| Yang, X | 1 |
| Song, Q | 1 |
| Cao, Z | 1 |
| Shi, Y | 1 |
| Deng, Y | 1 |
| Zhang, L | 1 |
| Raj, MA | 1 |
| Gowthaman, NS | 1 |
| John, SA | 1 |
| SIGWALD, J | 2 |
| ALLEVA, PM | 1 |
| CHRISTIANSEN, J | 1 |
| DALSGAARD-NIELSEN, T | 1 |
| Tan, EK | 1 |
| Cheah, SY | 1 |
| Fook-Chong, S | 1 |
| Yew, K | 1 |
| Chandran, VR | 1 |
| Lum, SY | 1 |
| Yi, Z | 1 |
| Namba, S | 2 |
| Ishimitsu, H | 1 |
| Nakasone, S | 1 |
| Vaĭnshtok, AB | 1 |
| Gonce, M | 1 |
| Barbeau, A | 1 |
| Bianchine, JR | 2 |
| Shaw, GM | 1 |
| Hanzal, F | 1 |
| Omoto, T | 1 |
| Kishikawa, H | 1 |
| Johnson, RD | 1 |
| Ruthven, CR | 1 |
| Goodwin, BL | 1 |
| Sandler, M | 1 |
| Langan, RJ | 1 |
| Cotzias, GC | 5 |
| Martocci, RJ | 1 |
| Mars, H | 4 |
| Naess, K | 1 |
| Burton, K | 1 |
| Hunter, KR | 1 |
| Stern, GM | 1 |
| Laurence, DR | 1 |
| Weiss, JL | 1 |
| Ng, LK | 1 |
| Chase, TN | 1 |
| Mozzis, CE | 1 |
| Prange, AJ | 2 |
| Hall, CD | 2 |
| Weiss, EA | 2 |
| Johnston, GA | 1 |
| Tran, N | 1 |
| Carter, AB | 2 |
| Tzavellas, O | 1 |
| Hartmann-von Monakow, K | 1 |
| Schmutzler, F | 1 |
| Eichhorn, A | 1 |
| Ericsson, AD | 1 |
| McCann, DS | 1 |
| Mazzoni, S | 1 |
| Toffano, G | 1 |
| Castellani, A | 1 |
| Papavasiliou, PS | 3 |
| Düby, SE | 1 |
| Steck, AJ | 1 |
| Fehling, C | 1 |
| Bell, MA | 1 |
| Yahr, MD | 4 |
| Duvoisin, RC | 3 |
| Côté, L | 1 |
| Cohen, G | 2 |
| Pfeiffer, RF | 1 |
| Cassell, K | 1 |
| Shaw, K | 1 |
| Stern, G | 1 |
| Lakke, JP | 1 |
| Nienhuis, RJ | 1 |
| Meyer, R | 1 |
| Zwols, F | 1 |
| Schut, T | 1 |
| Kuzuya, F | 2 |
| Wakita, T | 2 |
| Kawahara, H | 2 |
| Mawatari, S | 1 |
| Izumi, K | 1 |
| Kuroiwa, Y | 1 |
| Tkachev, RA | 1 |
| Markova, ED | 1 |
| Gotovtseva, EV | 1 |
| Barkhatova, VP | 1 |
| Ivanova-Smolenskaia, IA | 1 |
| Hsu, TH | 1 |
| Preziosi, TJ | 1 |
| Messiha, FS | 1 |
| Klawans, HL | 3 |
| Ringel, SP | 2 |
| Wolf, SM | 1 |
| Davis, RL | 1 |
| Lawrence, WH | 1 |
| Gehlen, W | 1 |
| Fahn, S | 1 |
| Mumenthaler, M | 1 |
| Kaeser, HE | 1 |
| Ferel, D | 1 |
| Wurmser, P | 1 |
| Diemath, HE | 1 |
| Enge, S | 1 |
| Lechner, H | 1 |
| Lipman, IJ | 1 |
| Ginos, J | 1 |
| Steck, A | 1 |
| Düby, S | 1 |
| Morris, CE | 1 |
| Van Woert, MH | 1 |
| Barrera, ER | 1 |
| Bennett, S | 1 |
| Pfeiffer, R | 1 |
| Ebadi, M | 1 |
| Castaigne, P | 1 |
| Rondot, P | 1 |
| Ribadeau-Dumas, JL | 1 |
| Shenker, DM | 1 |
| Cote, LJ | 1 |
| Abrams, WB | 2 |
| Coutinho, CB | 1 |
| Leon, AS | 2 |
| Spiegel, HE | 2 |
| Thomas, G | 1 |
| Coté, LD | 1 |
| Jameson, HD | 1 |
| Golden, RL | 1 |
| Mortati, FS | 1 |
| Schroeter, GA | 1 |
| Friedman, SA | 1 |
| Kott, E | 1 |
| Bornstein, B | 1 |
| Eichhorn, F | 1 |
| Cabot, EE | 1 |
9 reviews available for pyridoxine and Parkinson Disease
| Article | Year |
|---|---|
[The current treatment of Parkinson's disease].
Topics: Amantadine; Antidepressive Agents, Tricyclic; Dihydroxyphenylalanine; Drug Combinations; Histamine A | 1976 |
Clinical pharmacokinetics of levodopa in parkinson's disease.
Topics: Carboxy-Lyases; Cardiovascular Diseases; Dopamine; Dose-Response Relationship, Drug; Dyskinesia, Dru | 1976 |
Recent advances in the treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Carbidopa; Depression, Chemical; | 1975 |
[Antiparkinson agents. 50].
Topics: Atropine; Dihydroxyphenylalanine; Diphenhydramine; Histamine H1 Antagonists; Humans; Mephenesin; Mon | 1970 |
Pyridoxine, DOPA, and Parkinsonism.
Topics: Administration, Oral; Clinical Trials as Topic; Dihydroxyphenylalanine; Drug Antagonism; Drug Intera | 1972 |
Comments on the adverse effect of concurrent pyridoxine administration on the efficacy of L-dopa in treating parkinsonism.
Topics: Dihydroxyphenylalanine; Drug Interactions; Humans; Models, Biological; Parkinson Disease; Pyridoxine | 1972 |
[Clinical aspects and drug therapy of Parkinson's syndrome].
Topics: Amphetamine; Diphenhydramine; Humans; Parasympatholytics; Parkinson Disease; Parkinson Disease, Post | 1966 |
L-dopa therapy in Parkinson's disease.
Topics: Delirium; Depression; Dihydroxyphenylalanine; Gastrointestinal Hemorrhage; Hallucinations; Humans; H | 1971 |
Metabolic modification of Parkinson's disease and of chronic manganese poisoning.
Topics: Animals; Brain; Choline; Chronic Disease; Dihydroxyphenylalanine; Drug Synergism; Humans; Manganese | 1971 |
4 trials available for pyridoxine and Parkinson Disease
| Article | Year |
|---|---|
Functional COMT variant predicts response to high dose pyridoxine in Parkinson's disease.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Catechol O-Methyltransferase; Cross-Over Stu | 2005 |
[Treatment of Parkinson's syndrome with L-dopa and L-carbidopa (author's transl)].
Topics: Adult; Aged; Carbidopa; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Combination | 1976 |
Levodopa in Parkinsonism: potentiation of central effects with a peripheral inhibitor.
Topics: Administration, Oral; Adult; Biotransformation; Brain; Carbon Monoxide Poisoning; Cerebral Palsy; Ch | 1972 |
Pyridoxine, DOPA, and Parkinsonism.
Topics: Administration, Oral; Clinical Trials as Topic; Dihydroxyphenylalanine; Drug Antagonism; Drug Intera | 1972 |
68 other studies available for pyridoxine and Parkinson Disease
| Article | Year |
|---|---|
Vitamin B6 Deficiency Anemia Attributed to Levodopa/Carbidopa Intestinal Gel Therapy for Parkinson's Disease: A Diagnostic Pitfall for Myelodysplastic Syndrome with Ring Sideroblasts.
Topics: Aged; Anemia; Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Levodopa; Male; Myel | 2022 |
Vitamins B6 and B12, levodopa, and their complex interactions in patients with Parkinson's disease.
Topics: Humans; Levodopa; Parkinson Disease; Pyridoxine; Vitamin B 6; Vitamins | 2022 |
Reply: Vitamins B6 and B12, levodopa, and their complex interactions in patients with Parkinson's disease.
Topics: Humans; Levodopa; Parkinson Disease; Pyridoxine; Vitamin B 6; Vitamins | 2022 |
Pyridoxine-resveratrol hybrids as novel inhibitors of MAO-B with antioxidant and neuroprotective activities for the treatment of Parkinson's disease.
Topics: Animals; Antioxidants; Humans; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase In | 2020 |
Highly sensitive interference-free electrochemical determination of pyridoxine at graphene modified electrode: Importance in Parkinson and Asthma treatments.
Topics: Asthma; Carbon; Electrochemical Techniques; Electrodes; Graphite; Oxides; Parkinson Disease; Particl | 2016 |
[Indications for large doses of pyridoxine in neurology: Parkinson's disease, tremor of action (essential, lenticular and toxic tremor)].
Topics: Humans; Lens, Crystalline; Lenses; Neurology; Parkinson Disease; Pyridoxine; Tremor; Vitamin B 6 | 1957 |
[On the therapeutic effects of high doses of pyridoxine in extrapyramidal syndromes].
Topics: Basal Ganglia Diseases; Parkinson Disease; Pyridoxine; Spasm; Syndrome; Vitamin B 6 | 1960 |
[Treatment of paralysis agitans with vitamin B6 (pyridoxine)].
Topics: Humans; Parkinson Disease; Pyridoxine; Vitamin B 6 | 1962 |
[Treatment of paralysis agitans with pyridoxine].
Topics: Parkinson Disease; Pyridoxine | 1962 |
[Clinical significance of pyridoxine administration in L-dopa therapy of Parkinsonism (author's transl)].
Topics: Adult; Aged; Animals; Brain Chemistry; Carboxy-Lyases; Dopamine; Drug Therapy, Combination; Female; | 1980 |
[Treatment of parkinsonism with large doses of vitamin B6].
Topics: Aged; Antiparkinson Agents; Female; Humans; Male; Middle Aged; Parkinson Disease; Pyridoxine | 1979 |
[Effects of simultaneous administration of pyridoxine in the combined administration of L-dopa and peripheral decarboxylase inhibitors. Experimental and clinical studies].
Topics: Animals; Carbidopa; Carboxy-Lyases; Dogs; Drug Therapy, Combination; Female; Haplorhini; Humans; Lev | 1976 |
In vivo assessment of decarboxylase inhibition or potentiation: urinary dopamine and L-dopa output after L-dopa administration.
Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Carbidopa; Dopamine; Drug Intera | 1976 |
Do's and don'ts for the patient on levodopa therapy.
Topics: Aromatic Amino Acid Decarboxylase Inhibitors; Diet; Dietary Proteins; Drug Antagonism; Ethanol; Huma | 1976 |
Effect of chronic levodopa treatment on pyridoxine metabolism.
Topics: Aged; Erythrocytes; Humans; Levodopa; Middle Aged; Parkinson Disease; Plasma; Pyridoxal Phosphate; P | 1975 |
[Pyridoxine (vitamin B 6) and parkinsonism].
Topics: Adult; Aged; Humans; Middle Aged; Parkinson Disease; Pyridoxine | 1975 |
The treatment of tremor.
Topics: Adrenergic beta-Antagonists; Alcoholic Beverages; Cerebellar Diseases; Humans; Isoniazid; Levodopa; | 1987 |
Use of levodopa with other drugs.
Topics: Adult; Aged; Antidepressive Agents; Antiemetics; Digoxin; Dihydroxyphenylalanine; Diuretics; Drug An | 1970 |
L-dopa. II.
Topics: Anorexia Nervosa; Cardiac Complexes, Premature; Dihydroxyphenylalanine; Drug Synergism; Humans; Hypo | 1970 |
Long-lasting dyskinesia induced by levodopa.
Topics: Adult; Dihydroxyphenylalanine; Female; Humans; Injections; Injections, Intramuscular; Movement Disor | 1971 |
Inefficacy of tryptophan-pyridoxine in essential tremor.
Topics: Basal Ganglia; Dihydroxyphenylalanine; Drug Synergism; Female; Humans; Male; Parkinson Disease; Pyri | 1971 |
L-dopa and vitamin B 6 .
Topics: Chemical Phenomena; Chemistry; Dihydroxyphenylalanine; Humans; Parkinson Disease; Pyridoxine | 1971 |
Levodopa.
Topics: Dihydroxyphenylalanine; Humans; Parkinson Disease; Phenylacetates; Pyridoxine; Time Factors | 1971 |
L-Dopa and pyridoxine.
Topics: Decarboxylation; Dihydroxyphenylalanine; Dopamine; Humans; Oxidation-Reduction; Parkinson Disease; P | 1972 |
Letter: Pyridoxine contraindicated in parkinsonism.
Topics: Dihydroxyphenylalanine; Drug Antagonism; Humans; Metoclopramide; Nausea; Parkinson Disease; Pyridoxi | 1973 |
Letter: Pyridoxine in parkinsonism.
Topics: Dihydroxyphenylalanine; Drug Antagonism; Drug Interactions; Humans; Metoclopramide; Movement Disorde | 1973 |
[The effect of vitamin B 12 in combination with 4-chlortestosterone acetate on Parkinson's syndrome and hyperkinesia].
Topics: Adult; Aged; Blood Pressure; Body Weight; Drug Tolerance; Female; Folic Acid; Humans; Hyperkinesis; | 1967 |
[Specific therapy of extrapyramidal-motor syndromes].
Topics: Analgesics; Athetosis; Chorea; Datura stramonium; Dihydroxyphenylalanine; Dystonia Musculorum Deform | 1969 |
[The essentially tremulous forms of Parkinson's syndrome. Prognostic importance of a mixed tremor (combined intention tremor and resting tremor)].
Topics: Humans; Motor Activity; Parkinson Disease; Pyridoxine; Tremor | 1968 |
Dihydroxyphenylacetic acid in the treatment of Parkinsonism.
Topics: Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Drug Therapy, Combination; Enzyme Inh | 1974 |
[Effect of brain cortex phospholipids on some enzymatic reactions of cerebral amino acid decarboxylation and possible therapeutic implications (author's transl)].
Topics: Amino Acids; Animals; Brain; Cerebral Cortex; Decarboxylation; Humans; Mice; Parkinson Disease; Phos | 1974 |
A computerised tracking technique for the assessment of Parkinsonian motor disabilities.
Topics: Adult; Aged; Diagnosis, Computer-Assisted; Dihydroxyphenylalanine; Disability Evaluation; Evaluation | 1973 |
[L-DOPA with the decarboxylase inhibitor Ro 4-4602 in the treatment of Parkinson's disease].
Topics: Aromatic Amino Acid Decarboxylase Inhibitors; Dihydroxyphenylalanine; Humans; Parkinson Disease; Pyr | 1972 |
[Symposium: metabolism in neurological disorders. 1. Parkinsonism. 1-(2). Dopamin metabolism in urine and brain of patients with parkinsonism, with special reference to vitamin B 6 and L-DOPA-treatment].
Topics: Animals; Brain; Dihydroxyphenylalanine; Dopamine; Humans; Male; Parkinson Disease; Pyridoxine; Rats | 1972 |
[L-dopa treatment and vitamin B 6 --clinical and chemical studies].
Topics: Aged; Dihydroxyphenylalanine; Female; Humans; Male; Middle Aged; Parkinson Disease; Pyridoxine | 1972 |
Levodopa and related drugs.
Topics: Amantadine; Apomorphine; Dihydroxyphenylalanine; Humans; Hydrazines; Hypotension; Mental Disorders; | 1973 |
[Principles of the pathogenetic therapy of congenital extrapyramidal diseases].
Topics: Adolescent; Adult; Atropine; Basal Ganglia Diseases; Chelating Agents; Chronic Disease; Dihydroxyphe | 1973 |
Effect of pyridoxine on levodopa metabolism in normal and parkinsonian subjects.
Topics: Aged; Dihydroxyphenylalanine; Humans; Middle Aged; Parkinson Disease; Pharmaceutic Aids; Pyridoxine; | 1973 |
L-Dopa, B 6 , and alpha-methyldopa hydrazine.
Topics: Adult; Aged; Aromatic Amino Acid Decarboxylase Inhibitors; Brain; Carbidopa; Dihydroxyphenylalanine; | 1973 |
Permanent dementia in idiopathic Parkinsonism treated with levodopa.
Topics: Aged; Amantadine; Brain; Dihydroxyphenylalanine; Electroencephalography; Humans; Male; Parkinson Dis | 1973 |
Levodopa and dopamine in cerebrospinal fluid.
Topics: Aged; Aromatic Amino Acid Decarboxylase Inhibitors; Benztropine; Carbidopa; Dihydroxyphenylalanine; | 1973 |
[Administration of L-dopa in Parkinson's syndrome and vitamin B6 metabolism].
Topics: Aged; Dihydroxyphenylalanine; Female; Humans; Male; Middle Aged; Parkinson Disease; Pyridoxine | 1973 |
Letter: Pyridoxine and Parkinsonism.
Topics: Dihydroxyphenylalanine; Humans; Nausea; Parkinson Disease; Pyridoxine | 1973 |
Metabolic interactions of pyridoxine, levodopa, and carbidopa in Parkinson's disease.
Topics: Brain; Carbidopa; Dihydroxyphenylalanine; Dopa Decarboxylase; Dopamine; Homovanillic Acid; Humans; H | 1973 |
Levodopa, carbidopa, and pyridoxine in Parkinson disease. Metabolic interactions.
Topics: Carbidopa; Dihydroxyphenylalanine; Dopa Decarboxylase; Dopamine; Drug Interactions; Drug Synergism; | 1974 |
[Differential treatment of Parkinson's disease, with special reference to the possibility of iatrogenic disorders (author's transl)].
Topics: Amantadine; Anesthetics; Anti-Bacterial Agents; Antidepressive Agents; Antihypertensive Agents; Anti | 1974 |
"On-off" phenomenon with levodopa therapy in Parkinsonism. Clinical and pharmacologic correlations and the effect of intramuscular pyridoxine.
Topics: Adult; Carbidopa; Dihydroxyphenylalanine; Drug Synergism; Evaluation Studies as Topic; Female; Homov | 1974 |
[Treatment of Parkinson's syndrome with L-dopa].
Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents, Urinary; Antihypertensive Agents; Barbiturates; | 1970 |
EEG depth leads during stereotaxic brain surgery. A report on 117 cases (5 target points, effects of 13 different drugs).
Topics: Amides; Amygdala; Antimetabolites; Asparagine; Benzoates; Brain; Brain Diseases; Cerebrovascular Cir | 1970 |
Rapid deterioration in patients with parkinsonism following tryptophan-pyridoxine administration.
Topics: Adult; Brain; Drug Synergism; Humans; Male; Middle Aged; Parkinson Disease; Pyridoxine; Reaction Tim | 1972 |
Low pyridoxine diet in parkinsonism.
Topics: Diet Therapy; Dihydroxyphenylalanine; Humans; Parkinson Disease; Pyridoxine; Vitamin B 6 Deficiency | 1972 |
Levadopa and pyridoxine.
Topics: Animals; Brain; Carboxy-Lyases; Decarboxylation; Dihydroxyphenylalanine; Drug Interactions; Humans; | 1972 |
Pyridoxine and levodopa in the treatment of Parkinsonism.
Topics: Dihydroxyphenylalanine; Humans; Parkinson Disease; Pyridoxine | 1972 |
On the mechanism of the nullification of CNS effects of L-DOPA by pyridoxine in Parkinsonian patients.
Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Basal Ganglia; Benzyl Compounds; Dihydroxyphe | 1972 |
[Medical treatment of Parkinson's disease].
Topics: Amantadine; Carboxy-Lyases; Dihydroxyphenylalanine; Humans; Parasympatholytics; Parkinson Disease; P | 1972 |
Effect of vitamin B 6 on levodopa-induced changes in spinal fluid homovanillic acid.
Topics: Dihydroxyphenylalanine; Dopamine; Female; Humans; Middle Aged; Parkinson Disease; Phenylacetates; Py | 1971 |
Failure of vitamin B6 to reverse the L-dopa effect in patients on a dopa decarboxylase inhibitor.
Topics: Adult; Aged; Aromatic Amino Acid Decarboxylase Inhibitors; Dihydroxyphenylalanine; Dopa Decarboxylas | 1971 |
The metabolism of orally administered L-dopa in Parkinson patients.
Topics: Dihydroxyphenylalanine; Dopamine; Epinephrine; Humans; Norepinephrine; Parkinson Disease; Phenylacet | 1971 |
Absorption and metabolism of levodopa.
Topics: Animals; Decarboxylation; Dihydroxyphenylalanine; Dogs; Dopamine; Humans; Intestinal Absorption; Liv | 1971 |
Pyridoxine antagonism of levodopa in parkinsonism.
Topics: Aged; Chromatography, Thin Layer; Decarboxylation; Dihydroxyphenylalanine; Dopamine; Female; Humans; | 1971 |
Pyridoxine reversal of L-dopa effects in Parkinsonism.
Topics: Chorea; Dihydroxyphenylalanine; Humans; Parkinson Disease; Pyridoxine | 1969 |
Metabolic modification of some neurologic disorders.
Topics: Dihydroxyphenylalanine; Dopamine; Humans; Male; Manganese; Manganese Poisoning; Parkinson Disease; P | 1969 |
Pyridoxine for levodopa-induced dystonia.
Topics: Dihydroxyphenylalanine; Humans; Male; Middle Aged; Muscular Diseases; Parkinson Disease; Pyridoxine; | 1970 |
Levodopa, pyridoxine, and the burning feet syndrome.
Topics: Aged; Dihydroxyphenylalanine; Drug Antagonism; Foot Diseases; Humans; Male; Parkinson Disease; Pyrid | 1970 |
Levodopa and pyridoxine-deficient states.
Topics: Dihydroxyphenylalanine; Humans; Parkinson Disease; Pyridoxine; Vitamin B 6 Deficiency | 1970 |
Excretion of dopa metabolites.
Topics: Dihydroxyphenylalanine; Dopamine; Humans; Parkinson Disease; Phenylacetates; Pyridoxine | 1971 |
[Vitamin tablets and patients with parkinsonism].
Topics: Dihydroxyphenylalanine; Humans; Parkinson Disease; Pyridoxine; Vitamins | 1971 |
Physician's advice needed in diets for Parkinsonism.
Topics: Diet; Dihydroxyphenylalanine; Food Service, Hospital; Humans; Parkinson Disease; Pyridoxine | 1971 |